Test Price
2,800 AEDโ Home Collection Available
NRAS Gene Sequencing (Exons 2โ3) โ NGS-Based Mutation Analysis in UAE
Executive Summary & Core Metrics
DNA Labs UAE delivers clinically actionable insights through high-fidelity genomic sequencing. This ISO-accredited analysis identifies somatic and germline variants within the NRAS oncogene, directly informing targeted cancer therapy and hereditary risk assessment.
- Diagnostic Performance: 99.9% analytical sensitivity via deep NGS coverage (โฅ1000x).
- Collection Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection available daily (8 AM to 11 PM).
- Post-Test Guidance: Telephonic consultation and result interpretation by a Consultant Medical Geneticist.
- Insurance & Billing: Direct billing verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
This targeted next-generation sequencing assay interrogates exons 2 and 3 of the NRAS gene, encompassing hotspot codons 12, 13, and 61. The test detects single nucleotide variants and small insertions/deletions critical for guiding MEK inhibitor therapy and assessing hereditary cancer predisposition.
| Feature | Our NGS Test | Conventional Sanger Sequencing |
|---|---|---|
| Methodology | Ultra-Deep Next-Generation Sequencing (NGS) | Sanger Capillary Electrophoresis |
| Detection Sensitivity | โฅ1% variant allele frequency (low-level mutations) | 15โ20% variant allele frequency minimum |
| Turnaround Time | 3โ4 Weeks | 4โ6 Weeks |
| Exon Coverage | Full Exons 2 & 3, including splicing regions | Often limited to a single exon or hotspot |
Physician Insight & Safety Protocols
โThe clinical interpretation of NRAS variants requires integration with the patient's tumour histology and family pedigree. A mutation identified through this NGS assay provides a molecular target for therapy, but its prognostic weight is best determined within a multi-disciplinary framework. As a Consultant Medical Geneticist, I recommend coupling this test with a comprehensive hereditary cancer risk assessment for optimal clinical utility.โ
โ Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403
Medication & Clinical Considerations
⚠ Do not discontinue prescribed medication without consulting your doctor. Inform your physician of all active medications, supplements, and herbal remedies, as these may influence metabolic pathways and confound molecular test results.
Exclusion Criteria & Emergency Red Flags
- Exclusion: Patients under 18 years without a legal guardian's informed consent.
- Exclusion: Active systemic infection or febrile illness at the time of phlebotomy.
- Exclusion: Inability to provide a whole blood specimen or extracted DNA of sufficient quantity and quality.
- Red Flag: Seek immediate emergency care if you experience sudden, severe bleeding, syncope, or signs of infection at the phlebotomy site.
Patient FAQ & Clinical Guidance
1. What is the clinical utility of the NRAS gene sequencing test?
This NGS assay detects mutations in exons 2 and 3 of the NRAS gene. Results guide targeted therapy selection, particularly in melanoma and colorectal adenocarcinoma, and help stratify hereditary cancer risk. Variants are validated and interpreted by a Consultant Medical Geneticist.
2. What is the pre-test preparation protocol?
A mandatory genetic counselling session must precede sample collection to document a detailed three-generation family pedigree and obtain informed consent. A whole blood specimen (8-10 mL EDTA) or extracted DNA is required. No fasting is necessary, but you must provide a complete current medication list.
3. What is the post-test clinical support process?
Results are issued within 3-4 weeks of sample receipt. A telephonic consultation with a Consultant Medical Geneticist is included to interpret the report and provide followโup recommendations for clinical management or cascade screening of at-risk family members.
UAE Regulatory & Data Privacy Adherence
Commitment to Confidentiality: DNA Labs UAE strictly adheres to the Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient data is encrypted, access-restricted, and never shared without explicit consent. Clinical safety and patient consent are governed by Federal Decree-Law No. 4 of 2016 on Medical Liability. Our DHA-licensed facility ensures that all sample processing and data storage meet the highest standards of security and integrity.
For any privacy inquiries, please contact our Data Protection Officer at the lab or via our official channels.
Clinical & Logistical Metadata
| Test Name | NRAS Gene Sequencing (Exons 2-3) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3-4 Weeks |
| Sample Type / Matrix | Whole Blood (EDTA), Extracted DNA, or Dried Blood Spots (FTA Card) |
| Methodology Used | Ultra-Deep Next-Generation Sequencing (NGS) โ โฅ1000x coverage |
| ICD-10-CM Code | Z15.09, Z13.71 |
| LOINC Code | 46035-3 |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
ุฏุนู ุซูุงุฆู ุงููุบุฉ ู ุชุงุญ
ุงูุชุญูู ู ู ุงูุชุบุทูุฉ ุงูุชุฃู ูููุฉ
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
ุชููู ุนู ุงูุชุฎู ูู. ุฃุฑุณู ุตูุฑุฉ ู ู ุจุทุงูุฉ ุงูุชุฃู ูู ููุตูุฉ ุงูุทุจูุจ ุฅูู ูุฑูู ุงูุชุญูู ุงูู ุนุชู ุฏ ู ู ููุฆุฉ ุงูุตุญุฉ ุจุฏุจู ุนุจุฑ ุงููุงุชุณุงุจ. ุงุญุตู ุนูู ุชุญุฏูุซ ุงูุญุงูุฉ ูู ุฏูุงุฆู.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians